TSE:FRX Fennec Pharmaceuticals (FRX) Stock Price, News & Analysis → $5,000 Gold? (From Stansberry Research) (Ad) Free FRX Stock Alerts C$12.58 0.00 (0.00%) (As of 05/1/2024 ET) Add Compare Share Share Today's RangeC$12.58▼C$12.5850-Day RangeC$12.02▼C$15.2052-Week RangeC$9.27▼C$15.43VolumeN/AAverage Volume723 shsMarket CapitalizationC$340.92 millionP/E RatioN/ADividend Yield2.02%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesStock AnalysisChartCompetitorsEarningsHeadlinesInsider Trades Get Fennec Pharmaceuticals alerts: Email Address Ad The Freeport SocietyNew Trump BombshellI believe Donald J. Trump will go down as America’s last Republican president. But NOT for the reasons you may think… Click here to see my 2024 election prediction. About Fennec Pharmaceuticals Stock (TSE:FRX)Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.Read More FRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FRX Stock News HeadlinesApril 24, 2024 | insidertrades.comAdrian J. Haigh Sells 22,223 Shares of Fennec Pharmaceuticals Inc. (TSE:FRX) StockApril 17, 2024 | insidertrades.comFennec Pharmaceuticals Inc. (TSE:FRX) Senior Officer Adrian J. Haigh Acquires 22,222 SharesMay 2, 2024 | Stansberry Research (Ad)The Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.April 24, 2024 | americanbankingnews.comFennec Pharmaceuticals Inc. (TSE:FRX) Senior Officer Adrian J. Haigh Sells 22,223 Shares of StockApril 5, 2024 | finance.yahoo.comInsider Sell: CEO Rosty Raykov Sells 88,583 Shares of Fennec Pharmaceuticals Inc (FENC)April 1, 2024 | seekingalpha.comFRX:CA Fennec Pharmaceuticals Inc.March 23, 2024 | seekingalpha.comFennec Pharmaceuticals Inc. (FENC) Q4 2023 Earnings Call TranscriptMarch 22, 2024 | finance.yahoo.comFennec Pharmaceuticals Inc. (NASDAQ:FENC) Q4 2023 Earnings Call TranscriptMay 2, 2024 | Stansberry Research (Ad)The Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.March 21, 2024 | finanznachrichten.deFennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business UpdateMarch 19, 2024 | ca.finance.yahoo.comStocks in play: Fennec Pharmaceuticals Inc.March 17, 2024 | markets.businessinsider.comFennec, Norgine Reach Licensing Deal To Commercialize Pedmarqsi In Europe, Australia, & New ZealandFebruary 29, 2024 | finance.yahoo.comFennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 ResultsFebruary 23, 2024 | finance.yahoo.comFENC Mar 2024 10.000 callFebruary 1, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC) and Societal CDMO (SCTL)December 6, 2023 | finance.yahoo.comWith 31% stake, Fennec Pharmaceuticals Inc. (NASDAQ:FENC) seems to have captured hedge funds investors' interestDecember 1, 2023 | morningstar.comFennec Pharmaceuticals Inc FRXNovember 9, 2023 | seekingalpha.comFennec Pharmaceuticals Expands Possible TAM SignificantlyNovember 9, 2023 | finance.yahoo.comFennec Pharmaceuticals Inc. (NASDAQ:FENC) Reported Earnings Last Week And Analysts Are Already Upgrading Their EstimatesNovember 7, 2023 | finance.yahoo.comFennec Pharmaceuticals Inc. (NASDAQ:FENC) Q3 2023 Earnings Call TranscriptNovember 7, 2023 | finance.yahoo.comQ3 2023 Fennec Pharmaceuticals Inc Earnings CallNovember 3, 2023 | benzinga.comPreview: Fennec Pharmaceuticals's EarningsNovember 1, 2023 | finance.yahoo.comInvestors in Fennec Pharmaceuticals (NASDAQ:FENC) have unfortunately lost 20% over the last yearOctober 30, 2023 | finance.yahoo.comFennec Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 6, 2023October 5, 2023 | finance.yahoo.comAnalysts Expect Breakeven For Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Before LongSeptember 30, 2023 | theglobeandmail.comClosing Bell: Fennec Pharmaceuticals Inc up on Friday (FRX)August 23, 2023 | theglobeandmail.comFennec Pharmaceuticals: Top 10 Undervalued Healthcare Sector Stocks on TSX (FRX)See More Headlines Receive FRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today5/02/2024Next Earnings (Estimated)5/09/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:FRX CUSIPN/A CIKN/A Webfennecpharma.com Phone+1-919-6364530FaxN/AEmployees29Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.82) Trailing P/E RatioN/A Forward P/E Ratio29.67 P/E GrowthN/ANet IncomeC$-16,050,000.00 Net Margins-75.50% Pretax MarginN/A Return on Equity-1,005.59% Return on Assets-29.67% Debt Debt-to-Equity Ratio881.09 Current Ratio3.56 Quick Ratio10.17 Sales & Book Value Annual SalesC$21.25 million Price / Sales16.04 Cash FlowC$1.08 per share Price / Cash Flow11.66 Book ValueC($0.43) per share Price / Book-29.26Miscellaneous Outstanding Shares27,100,000Free FloatN/AMarket CapC$340.92 million OptionableNot Optionable Beta0.40 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Rostislav Raykov (Age 48)CEO & Director Comp: $1.22MMr. Robert C. Andrade (Age 49)Chief Financial Officer Comp: $826.82kMr. Adrian J. Haigh (Age 65)Chief Operating Officer Comp: $542.42kMr. Mark GowlandControllerMr. Lei FangPresident of Pharstat IncKey CompetitorsProMetic Life SciencesTSE:PLIVIVO CannabisCVE:ABCNEmblemCVE:EMCBriaCell TherapeuticsCVE:BCTImmunoPrecise AntibodiesCVE:IPAView All CompetitorsInsidersAdrian J. HaighSold 22,223 sharesTotal: C$207,029.47 ($9.32/share)Adrian J. HaighBought 22,222 shares on 4/15/2024Total: C$51,332.82 ($2.31/share)Chris Anigeron RallisSold 800 sharesTotal: C$8,360.00 ($10.45/share)Robert Christopher AndradeSold 13,975 sharesTotal: C$152,345.67 ($10.90/share)Chris Anigeron RallisSold 2,114 sharesTotal: C$23,190.58 ($10.97/share)View All Insider Transactions FRX Stock Analysis - Frequently Asked Questions How have FRX shares performed in 2024? Fennec Pharmaceuticals' stock was trading at C$15.16 on January 1st, 2024. Since then, FRX shares have decreased by 17.0% and is now trading at C$12.58. View the best growth stocks for 2024 here. When is Fennec Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our FRX earnings forecast. How were Fennec Pharmaceuticals' earnings last quarter? Fennec Pharmaceuticals Inc. (TSE:FRX) posted its earnings results on Thursday, March, 21st. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of $0.02 by $0.16. The biopharmaceutical company earned $13.25 million during the quarter, compared to analyst estimates of $12.88 million. Fennec Pharmaceuticals had a negative net margin of 75.50% and a negative trailing twelve-month return on equity of 1,005.59%. What other stocks do shareholders of Fennec Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Encanto Potash (EPO), Acadian Timber (ADN), Agellan Commercial Real Estate Invtmt TR (ACR.UN), AutoCanada (ACQ), ATCO (ACO.X), Accord Financial (ACD), Aurora Cannabis (ACB), Air Canada (AC) and Barrick Gold (ABX). How do I buy shares of Fennec Pharmaceuticals? Shares of FRX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:FRX) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingTrump just won 2024Porter & CompanyHe Is Giving Away BitcoinCrypto Swap ProfitsA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsThe A.I. story nobody is telling you (Read ASAP)TradeSmithAI “wealth window” is closing June 25thParadigm Press4 Cryptos BETTER than BitcoinTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fennec Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
